Everything tagged "biotech" across research, earnings, and macro.
20 articles
Danaher is seeing better operating momentum across Life Sciences, Diagnostics, and Biotechnology, but the stock still trades at a premium that limits upside. The report keeps a Buy rating with fair value set at $225.
Medpace is still delivering strong revenue, margin, and cash flow growth, but softer bookings and a rich valuation keep the stock in Hold territory. The business quality is high, yet the current setup looks better on pullbacks than at full price.
Biogen’s business has stabilized, with growth products and LEQEMBI helping offset legacy MS pressure. The stock still looks reasonably priced for a selective Buy as cash flow and mix improve.
Biogen’s selloff looks backward-looking. A newly approved home-start LEQEMBI formulation and fresh real-world stability data make the Alzheimer’s story easier to scale, not harder to believe.
Moderna’s latest drop looks more like regulatory panic than a broken thesis. With an Aug. 5 FDA decision now in sight and the flu program still under active review, the selloff looks overdone.
BridgeBio has evolved from a pipeline biotech into a commercial-stage rare-disease story, led by explosive Attruby sales and a late-stage pipeline. The stock still carries meaningful balance-sheet risk, but the launch momentum is real.
Alnylam has evolved into a commercial RNAi leader, with AMVUTTRA powering rapid revenue growth and a strong balance sheet supporting the next leg. The stock earns a Buy as the TTR franchise scales and profitability improves.
Summit Therapeutics is a high-risk, high-upside oncology story built around ivonescimab, with positive Phase III data and an FDA review underway. The stock looks attractive for investors willing to accept binary regulatory risk in exchange for platform-scale potential.
Vertex combines a dominant cystic fibrosis franchise with early diversification in rare disease and acute pain. The stock looks like a disciplined Buy, but valuation still depends on execution across ALYFTREK, CASGEVY, JOURNAVX, and the renal pipeline.
Moderna’s latest surge looks earned, not speculative. Science Day gave the market a concrete post-COVID roadmap, and the August 5 flu decision gives MRNA a real catalyst investors can actually underwrite.
BeiGene has crossed from cash-burning biotech into a profitable global oncology platform, powered by BRUKINSA’s rapid growth and a strengthening balance sheet. The pipeline still matters, but the investment case now rests on commercial execution and self-funding momentum.
Abivax just posted the kind of Phase 3 efficacy biotech investors wait years to see, and the stock still got cut nearly in half because the market fixated on a safety overhang. That risk is real, but a 44.1% one-day collapse looks more like panic repricing than a fair read on a drug that delivered 50%+ remission in maintenance.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator